Pfizer To Use India Location To Concentrate On Indian Ailments
This article was originally published in PharmAsia News
When Pfizer stepped up its presence in the Indian pharmaceutical market, it did so to concentrate on drugs specific to Indian ailments. With the move to India, Pfizer plans to focus on cancer, diabetes, inflammation, neurological disorders and other ailments at the regional level. Among the plans are trials of Sutent (sunitinib malate) for combating kidney cancer. Pfizer's India presence also is aimed at diabetes, inflammation and neurological disorders as well as breast, cervical and lung cancers. (Click here for more
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.